{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:57:24Z","timestamp":1763755044118,"version":"3.45.0"},"reference-count":70,"publisher":"Oncology Nursing Society (ONS)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2019,12,1]]},"DOI":"10.1188\/19.cjon.599-608","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T13:20:30Z","timestamp":1573824030000},"page":"599-608","source":"Crossref","is-referenced-by-count":2,"title":["Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation\u2013Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis"],"prefix":"10.1188","volume":"23","author":[{"given":"Ilene","family":"Galinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenn","family":"Fechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2019,12,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gasc\u00f3n, P., Glaspy, J., . . . Herrstedt, J. (2018). Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 29(Suppl.), iv96\u2013iv110. https:\/\/doi.org\/10.1093\/annonc\/mdx758","DOI":"10.1093\/annonc\/mdx758"},{"key":"2","unstructured":"American Cancer Society. (2019). Managing cancer-related side effects. Retrieved from http:\/\/www.cancer.org\/treatment\/treatments-and-side-effects\/physical-sid..."},{"key":"3","doi-asserted-by":"crossref","unstructured":"Arber, D.A., Borowitz, M.J., Cessna, M., Etzell, J., Foucar, K., Hasserjian, R.P., . . . Vardiman, J.W. (2017). Initial diagnostic workup of acute leukemia: Guideline from the College of American Pathologists and the American Society of Hematology. Archives of Pathology and Laboratory Medicine, 141, 1342\u20131393. https:\/\/doi.org\/10.5858\/arpa.2016-0504-CP","DOI":"10.5858\/arpa.2016-0504-CP"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., . . . Vardiman, J.W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127, 2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","DOI":"10.1182\/blood-2016-03-643544"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Arock, M., Akin, C., Hermine, O., & Valent, P. (2015). Current treatment options in patients with mastocytosis: Status in 2015 and future perspectives. European Journal of Haematology, 94, 474\u2013490. https:\/\/doi.org\/10.1111\/ejh.12544","DOI":"10.1111\/ejh.12544"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Bacher, U., Haferlach, C., Kern, W., Haferlach, T., & Schnittger, S. (2008). Prognostic relevance of FLT3-TKD mutations in AML: The combination matters\u2014An analysis of 3082 patients. Blood, 111, 2527\u20132537. https:\/\/doi.org\/10.1182\/blood-2007-05-091215","DOI":"10.1182\/blood-2007-05-091215"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Chatterjee, A., Ghosh, J., & Kapur, R. (2015). Mastocytosis: A mutated KIT receptor induced myeloproliferative disorder. Oncotarget, 6, 18250\u201318264. https:\/\/doi.org\/10.18632\/oncotarget.4213","DOI":"10.18632\/oncotarget.4213"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Cohen, S.S., Skovbo, S., Vestergaard, H., Kristensen, T., M\u00f8ller, M., Bindslev-Jensen, C., . . . Broesby-Olsen, S. (2014). Epidemiology of systemic mastocytosis in Denmark. British Journal of Haematology, 166, 521\u2013528. https:\/\/doi.org\/10.1111\/bjh.12916","DOI":"10.1111\/bjh.12916"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Cooper, B.W., Kindwall-Keller, T.L., Craig, M.D., Creger, R.J., Hamadani, M., Tse, W.W., & Lazarus, H.M. (2015). A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. Clinical Lymphoma, Myeloma and Leukemia, 15, 428\u2013432. https:\/\/doi.org\/10.1016\/j.clml.2015.02.017","DOI":"10.1016\/j.clml.2015.02.017"},{"key":"10","doi-asserted-by":"crossref","unstructured":"DeAngelo, D.J., George, T.I., Linder, A., Langford, C., Perkins, C., Ma, J., . . . Gotlib, J. (2018). Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia, 32, 470\u2013478. https:\/\/doi.org\/10.1038\/leu.2017.234","DOI":"10.1038\/leu.2017.234"},{"key":"11","doi-asserted-by":"crossref","unstructured":"del Corral, A., Dutreix, C., Huntsman-Labed, A., Lorenzo, S., Morganroth, J., Harrell, R., & Wang, Y. (2012). Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers. Journal of Clinical Pharmacology, 69, 1255\u20131263. https:\/\/doi.org\/10.1007\/s00280-012-1825-y","DOI":"10.1007\/s00280-012-1825-y"},{"key":"12","doi-asserted-by":"crossref","unstructured":"de Lima, M. (2015). New approaches to transplantation in acute myelogenous leukemia. Hematology ASH Education Program, 2015, 596\u2013604. https:\/\/doi.org\/10.1182\/asheducation-2015.1.596","DOI":"10.1182\/asheducation-2015.1.596"},{"key":"13","unstructured":"De Munter, J. (2012). Febrile neutropenia: The nursing perspective. Retrieved from https:\/\/bhs.be\/storage\/app\/media\/userfiles\/files\/General_Annual_Meetings..."},{"key":"14","doi-asserted-by":"crossref","unstructured":"de Naurois, J., Novitzky-Basso, I., Gill, M.J., Marti, F.M., Cullen, M.H., & Roila, F. (2010). Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Annals of Oncology, 21(Suppl.), v252\u2013v256. https:\/\/doi.org\/10.1093\/annonc\/mdq196","DOI":"10.1093\/annonc\/mdq196"},{"key":"15","doi-asserted-by":"crossref","unstructured":"D\u00f6hner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F.R., B\u00fcchner, T., . . . Bloomfield, C.D. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 129, 424\u2013447. https:\/\/doi.org\/blood-2016-08-733196","DOI":"10.1182\/blood-2016-08-733196"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Erben, P., Schwaab, J., Metzgeroth, G., Horny, H.P., Jawhar, M., Sotlar, K., . . . Reiter, A. (2014). The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Annals of Hematology, 93, 81\u201388. https:\/\/doi.org\/10.1007\/s00277-013-1964-1","DOI":"10.1007\/s00277-013-1964-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Escribano, L., Akin, C., Castells, M., & Schwartz, L.B. (2006). Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflammation and Allergy Drug Targets, 5, 61\u201377. https:\/\/doi.org\/10.2174\/187152806775269303","DOI":"10.2174\/187152806775269303"},{"key":"18","unstructured":"Fabbro, D., Ruetz, S., Bodis, S., Pruschy, M., Csermak, K., Man, A., . . . Meyer, T. (2000). PKC412\u2014A protein kinase inhibitor with a broad therapeutic potential. Anti-Cancer Drug Design, 15, 17\u201328."},{"key":"19","doi-asserted-by":"crossref","unstructured":"Fey, M.F. (2007). Normal and malignant hematopoiesis. Annals of Oncology, 18(Suppl.), i9\u2013i13. https:\/\/doi.org\/10.1093\/annonc\/mdl444","DOI":"10.1093\/annonc\/mdl444"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Fuller, S.J. (2012). New insights into the pathogenesis, diagnosis, and management of mastocytosis. Hematology\/Oncology Clinics of North America, 26, 1143\u20131168. https:\/\/doi.org\/10.1016\/j.hoc.2012.08.008","DOI":"10.1016\/j.hoc.2012.08.008"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Gallogly, M.M., & Lazarus, H.M. (2016). Midostaurin: An emerging treatment for acute myeloid leukemia patients. Journal of Blood Medicine, 7, 73\u201383. https:\/\/doi.org\/10.2147\/JBM.S100283","DOI":"10.2147\/JBM.S100283"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Ganjare, A., & Kulkarni, A.P. (2013). Comparative electrocardiographic effects of intravenous ondansetron and granisetron in patients undergoing surgery for carcinoma breast: A prospective single-blind randomised trial. Indian Journal of Anaesthesia, 57, 41\u201345. https:\/\/doi.org\/10.4103\/0019-5049.108560","DOI":"10.4103\/0019-5049.108560"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Garcia-Manero, G., Tambaro, F.P., Bekele, N.B., Yang, H., Ravandi, F., Jabbour, E., . . . Kantarjian, H.M. (2012). Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Journal of Clinical Oncology, 30, 2204\u20132210. https:\/\/doi.org\/10.1200\/JCO.2011.38.3265","DOI":"10.1200\/JCO.2011.38.3265"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Ghiaur, G., & Levis, M. (2017). Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment. Hematology\/Oncology Clinics of North America, 31, 681\u2013692. https:\/\/doi.org\/10.1016\/j.hoc.2017.04.005","DOI":"10.1016\/j.hoc.2017.04.005"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Gotlib, J., Kluin-Nelemans, H.C., George, T.I., Akin, C., Sotlar, K., Hermine, O., . . . Reiter, A. (2016). Efficacy and safety of midostaurin in advanced systemic mastocytosis. New England Journal of Medicine, 374, 2530\u20132541. https:\/\/doi.org\/10.1056\/NEJMoa1513098","DOI":"10.1056\/NEJMoa1513098"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Gotlib, J., Pardanani, A., Akin, C., Reiter, A., George, T., Hermine, O., . . . Valent, P. (2013). International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood, 121, 2393\u20132401. https:\/\/doi.org\/10.1182\/blood-2012-09-458521","DOI":"10.1182\/blood-2012-09-458521"},{"key":"27","unstructured":"Grover, N. (2017). U.S. FDA approves Novartis\u2019 leukemia treatment. Retrieved from http:\/\/www.reuters.com\/article\/us-novartis-fda\/u-s-fda-approves-novartis..."},{"key":"28","doi-asserted-by":"crossref","unstructured":"Izak, M., & Bussel, J.B. (2014). Management of thrombocytopenia. F1000prime Reports, 6, 45. https:\/\/doi.org\/10.12703\/P6-45","DOI":"10.12703\/P6-45"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Kappelle, W.F., Siersema, P.D., Bogte, A., & Vleggaar, F.P. (2016). Challenges in oral drug delivery in patients with esophageal dysphagia. Expert Opinion on Drug Delivery, 13, 645\u2013658. https:\/\/doi.org\/10.1517\/17425247.2016.1142971","DOI":"10.1517\/17425247.2016.1142971"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Kayser, S., Schlenk, R.F., Londono, M.C., Breitenbuecher, F., Wittke, K., Du, J., . . . D\u00f6hner, K. (2009). Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood, 114, 2386\u20132392. https:\/\/doi.org\/10.1182\/blood-2009-03-209999","DOI":"10.1182\/blood-2009-03-209999"},{"key":"31","unstructured":"Kebriaei, P., de Lima, M., & Estey, E. (2008). Management of acute leukemias. In V.T. DeVita, Jr., T.S. Lawrence, & S.A. Rosenberg (Eds.), DeVita, Hellman, and Rosenberg\u2019s cancer: Principles and practice of oncology (8th ed., pp. 2232\u20132265). Philadelphia, PA: Lippincott Williams and Wilkins."},{"key":"32","doi-asserted-by":"crossref","unstructured":"Krishnasamy, M., Kwok-Wei So, W., Yates, P., de Calvo, L.E., Annab, R., Wisniewski, T., & Aranda, S. (2014). The nurse\u2019s role in managing chemotherapy-induced nausea and vomiting: An international survey. Cancer Nursing, 37(4), E27\u2013E35. https:\/\/doi.org\/10.1097\/NCC.0b013e3182a3534a","DOI":"10.1097\/NCC.0b013e3182a3534a"},{"key":"33","unstructured":"Larson, R.A., Mandrekar, S.J., Sanford, B.L., Laumann, K., Geyer, S.M, Bloomfield, C.D., . . . Stone, R.M. (2017). An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603\/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. Blood, 130(Suppl.), 145."},{"key":"34","doi-asserted-by":"crossref","unstructured":"Montoya, L. (2007). Managing hematologic toxicities in the oncology patient. Journal of Infusion Nursing, 30, 168\u2013172. https:\/\/doi.org\/10.1097\/01.NAN.0000270676.59180.c3","DOI":"10.1097\/01.NAN.0000270676.59180.c3"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Nagata, H., Worobec, A.S., Oh, C.K., Chowdhury, B.A., Tannenbaum, S., Suzuki, Y., & Metcalfe, D.D. (1995). Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proceedings of the National Academy of Sciences of the United States of America, 92, 10560\u201310564. https:\/\/doi.org\/10.1073\/pnas.92.23.10560","DOI":"10.1073\/pnas.92.23.10560"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Nagel, G., Weber, D., Fromm, E., Erhardt, S., L\u00fcbbert, M., Fiedler, W., . . . Schlenk, R.F. (2017). Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Annals of Hematology, 96, 1993\u20132003. https:\/\/doi.org\/10.1007\/s00277-017-3150-3","DOI":"10.1007\/s00277-017-3150-3"},{"key":"37","unstructured":"National Cancer Institute. (2006). Common Terminology Criteria for Adverse Events (CTCAE) [v.3.0]. Retrieved from https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs..."},{"key":"38","unstructured":"National Cancer Institute. (2019). Cancer stat facts: Leukemia\u2014Acute myeloid leukemia (AML). Retrieved from https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"key":"39","unstructured":"National Comprehensive Cancer Network. (2019a). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Acute myeloid leukemia. [v.2.2020]. Retrieved from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf"},{"key":"40","unstructured":"National Comprehensive Cancer Network. (2019b). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Systemic mastocytosis [v.2.2019]. Retrieved from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mastocytosis.pdf"},{"key":"41","unstructured":"Novartis Europharm Limited. (2017). Rydapt\u00ae (midostaurin) [Summary of product characteristics]. Retrieved from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Info..."},{"key":"42","unstructured":"Novartis Pharmaceuticals. (2017a). Gleevec\u00ae (imatinib) [Package insert]. Retrieved from https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/file..."},{"key":"43","unstructured":"Novartis Pharmaceuticals. (2017b). Rydapt\u00ae (midostaurin) [Package insert]. Retrieved from https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/file..."},{"key":"44","unstructured":"Ouatas, T., Duval, V., Sinclair, K., & Berkowitz, N. (2017). Concomitant use of midostaurin with strong CYP3A4 inhibitors: An analysis from the RATIFY trial. Blood, 130(Suppl.), 3814."},{"key":"45","doi-asserted-by":"crossref","unstructured":"Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V.I., Paschka, P., Roberts, N.D., . . . Campbell, P.J. (2016). Genomic classification and prognosis in acute myeloid leukemia. New England Journal of Medicine, 374, 2209\u20132221. https:\/\/doi.org\/10.1056\/NEJMoa1516192","DOI":"10.1056\/NEJMoa1516192"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Pardanani, A. (2016). Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. American Journal of Hematology, 91, 1146\u20131159. https:\/\/doi.org\/10.1002\/ajh.24553","DOI":"10.1002\/ajh.24553"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Propper, D.J., McDonald, A.C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J.P., . . . Twelves, C. (2001). Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. Journal of Clinical Oncology, 19, 1485\u20131492. https:\/\/doi.org\/10.1200\/JCO.2001.19.5.1485","DOI":"10.1200\/JCO.2001.19.5.1485"},{"key":"48","unstructured":"Reiter, A., Kluin-Nelemans, H.C., George, T., Akin, C., DeAngelo, D.J., Hermine, O., . . . Gotlib, J. (2017). Pooled survival analysis of midostaurin clinical study data (D2201 + A2213) in patients with advanced systemic mastocytosis compared with historical controls. Haematologica, 102(Suppl. 2), 321\u2013322."},{"key":"49","doi-asserted-by":"crossref","unstructured":"Russell, A.M., Olive, S., Lines, S., Murphy, A., Hocking, J., Newell, K., . . . Burge, G. (2018). Contemporary challenges for specialist nursing in interstitial lung disease. Breathe, 14(1), 36\u201341. https:\/\/doi.org\/10.1183\/20734735.014917","DOI":"10.1183\/20734735.014917"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Schlenk, R.F., Kayser, S., Bullinger, L., Kobbe, G., Casper, J., Ringhoffer, M., . . . D\u00f6hner, K. (2014). Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood, 124, 3441\u20133449. https:\/\/doi.org\/10.1182\/blood-2014-05-578070","DOI":"10.1182\/blood-2014-05-578070"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Schlenk, R.F., Weber, D., Fiedler, W., Salih, H.R., Wulf, G., Salwender, H., . . . D\u00f6hner, H. (2019). Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood, 133, 840\u2013851. https:\/\/doi.org\/10.1182\/blood-2018-08-869453","DOI":"10.1182\/blood-2018-08-869453"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Shallis, R.M., Wang, R., Davidoff, A., Ma, X., & Zeidan, A.M. (2019). Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews, 36, 70\u201387. https:\/\/doi.org\/10.1016\/j.blre.2019.04.005","DOI":"10.1016\/j.blre.2019.04.005"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Shomali, W., & Gotlib, J. (2018). The new tool \u201cKIT\u201d in advanced systemic mastocytosis. Hematology ASH Education Program Book, 2018, 127\u2013136. https:\/\/doi.org\/10.1182\/asheducation-2018.1.127","DOI":"10.1182\/asheducation-2018.1.127"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Sokol, H., Georgin-Lavialle, S., Canioni, D., Barete, S., Damaj, G., Soucie, E., . . . Hermine, O. (2013). Gastrointestinal manifestations in mastocytosis: A study of 83 patients. Journal of Allergy and Clinical Immunology, 132, 866\u2013873. https:\/\/doi.org\/10.1016\/j.jaci.2013.05.026","DOI":"10.1016\/j.jaci.2013.05.026"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Sotak, M.L., Marin, M., Coombs, J., & Teitelbaum, A. (2012). PSY23 burden of illness of aggressive systemic mastocytosis (ASM) in the United States. Value in Health, 15(4), A102. https:\/\/doi.org\/10.1016\/j.jval.2012.03.557","DOI":"10.1016\/j.jval.2012.03.557"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Sperr, W.R., & Valent, P. (2012). Diagnosis, progression patterns and prognostication in mastocytosis. Expert Review of Hematology, 5, 261\u2013274. https:\/\/doi.org\/10.1586\/ehm.12.12","DOI":"10.1586\/ehm.12.12"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Stone, R.M., Mandrekar, S.J., Sanford, B.L., Laumann, K., Geyer, S., Bloomfield, C.D., . . . D\u00f6hner, H. (2017). Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. New England Journal of Medicine, 377, 454\u2013464. https:\/\/doi.org\/10.1056\/NEJMoa1614359","DOI":"10.1056\/NEJMoa1614359"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Strati, P., Kantarjian, H., Ravandi, F., Nazha, A., Borthakur, G., Daver, N., . . . Cortes, J. (2015). Phase I\/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. American Journal of Hematology, 90, 276\u2013281. https:\/\/doi.org\/10.1002\/ajh.23924","DOI":"10.1002\/ajh.23924"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Talati, C., & Sweet, K. (2018). Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. Leukemia Research, 73, 58\u201366. https:\/\/doi.org\/10.1016\/j.leukres.2018.09.001","DOI":"10.1016\/j.leukres.2018.09.001"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Theoharides, T.C., Kempuraj, D., Tagen, M., Conti, P., & Kalogeromitros, D. (2007). Differential release of mast cell mediators and the pathogenesis of inflammation. Immunological Reviews, 217, 65\u201378. https:\/\/doi.org\/10.1111\/j.1600-065X.2007.00519.x","DOI":"10.1111\/j.1600-065X.2007.00519.x"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Thiede, C., Steudel, C., Mohr, B., Schaich, M., Sch\u00e4kel, U., Platzbecker, U., . . . Illmer, T. (2002). Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326\u20134335. https:\/\/doi.org\/10.1182\/blood.v99.12.4326","DOI":"10.1182\/blood.V99.12.4326"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Tvedt, T.H., Nepstad, I., & Bruserud, \u00d8. (2017). Antileukemic effects of midostaurin in acute myeloid leukemia\u2014The possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. Expert Opinion on Investigational Drugs, 26, 343\u2013355. https:\/\/doi.org\/10.1080\/13543784.2017.1275564","DOI":"10.1080\/13543784.2017.1275564"},{"key":"63","unstructured":"University of Texas MD Anderson Cancer Center. (2019). Adult antiemetic management of chemotherapy-induced nausea and vomiting (CINV). Retrieved from https:\/\/www.mdanderson.org\/content\/dam\/mdanderson\/documents\/for-physicia..."},{"key":"64","doi-asserted-by":"crossref","unstructured":"Valent, P. (2015). Diagnosis and management of mastocytosis: An emerging challenge in applied hematology. Hematology ASH Education Program, 2015, 98\u2013105. https:\/\/doi.org\/10.1182\/asheducation-2015.1.98","DOI":"10.1182\/asheducation-2015.1.98"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Valent, P., Akin, C., Hartmann, K., George, T.I., Sotlar, K., Peter, B., . . . Gotlib, J. (2017). Midostaurin: A magic bullet that blocks mast cell expansion and activation. Annals of Oncology, 28, 2367\u20132376. https:\/\/doi.org\/10.1093\/annonc\/mdx290","DOI":"10.1093\/annonc\/mdx290"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Valent, P., Akin, C., Hartmann, K., Nilsson, G., Reiter, A., Hermine, O., . . . Metcalfe, D.D. (2017). Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future. Cancer Research, 77, 1261\u20131270. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2234","DOI":"10.1158\/0008-5472.CAN-16-2234"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Valent, P., Akin, C., Sperr, W.R., Escribano, L., Arock, M., Horny, H.P., . . . Metcalfe, D.D. (2003). Aggressive systemic mastocytosis and related mast cell disorders: Current treatment options and proposed response criteria. Leukemia Research, 27, 635\u2013641. https:\/\/doi.org\/10.1016\/s0145-2126(02)00168-6","DOI":"10.1016\/S0145-2126(02)00168-6"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Valent, P., Sperr, W.R., & Akin, C. (2010). How I treat patients with advanced systemic mastocytosis. Blood, 116, 5812\u20135817. https:\/\/doi.org\/10.1182\/blood-2010-08-292144","DOI":"10.1182\/blood-2010-08-292144"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Vega-Olivo, M., & Criner, G.J. (2018). Idiopathic pulmonary fibrosis: A guide for nurse practitioners. Nurse Practitioner, 43(5), 48\u201354. https:\/\/doi.org\/10.1097\/01.NPR.0000531121.07294.36","DOI":"10.1097\/01.NPR.0000531121.07294.36"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Yanada, M., Matsuo, K., Suzuki, T., Kiyoi, H., & Naoe, T. (2005). Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: A meta-analysis. Leukemia, 19, 1345\u20131349. https:\/\/doi.org\/10.1038\/sj.leu.2403838","DOI":"10.1038\/sj.leu.2403838"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/23\/6\/midostaurin-nursing-perspectives-managing-treatment-and-adverse-events-patients-flt3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:34Z","timestamp":1763754634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/23\/6\/midostaurin-nursing-perspectives-managing-treatment-and-adverse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1188\/19.cjon.599-608","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}